Adovate Accepted into JLABS, Global Incubator Network

Charlottesville, VA – May 15, 2025 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics targeting the adenosine receptors, today announced its acceptance into Johnson & Johnson’s global incubator network, JLABS.

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/

“We are honored to be part of JLABS, a globally recognized incubator program that fosters scientific discovery and accelerates the development of transformative healthcare solutions,” said William Stilley, Chief Executive Officer of Adovate. “As we continue our efforts to advance our lead compound, ADO-5030, through clinical development, we plan to leverage this membership to navigate key challenges and bring our novel therapy to patients in need.”

Read the full press release with this URL: https://adovate.com/news-release-may-15-2025/